I've given you my take. I'm frustrated not concerned....

I've given you my take. I'm frustrated not concerned.

Nothing has changed other than the share price. Given they don't have to raise it doesn't really matter as annoying as it is to watch.

IPOs with blue sky potential like this go through a honeymoon phase where they get bid up on potential and some proof. Only a hint in a good market. Then they hit a phase where the mkt wants solid proof they're executing or they keep going down. In a bad small cap mkt this is worse.

I thought LTP would be able to push through that but the placement and lack of big news has seen them suffer the same fate.

It doesn't mean anything other than they need to prove they're executing. As they prove that the share price will correct. If you run through their timeline and the likelihood of approval (better side effect profile, half dose, generic/diff delivery etc means >90% imo).

I cannot see a reason they don't execute despite all my efforts searching for one. I've hired a medical researcher to find holes, have consulted brokers and bio tech analysts on various issues. It all stands up.

My daily P&L swings on this are at times multiples of your investment. Despite the frustration I'm focussed on FDA, licensing agreements and the fact it's the fastest acting product in a giant mkt.